

Anthony Howell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5379169/publications.pdf>

Version: 2024-02-01

578
papers

49,800
citations

906

116
h-index

2127

203
g-index

590
all docs

590
docs citations

590
times ranked

34215
citing authors

#	ARTICLE	IF	CITATIONS
1	Uptake and efficacy of bilateral risk reducing surgery in unaffected female <i>BRCA1</i> and <i>BRCA2</i> carriers. <i>Journal of Medical Genetics</i> , 2022, 59, 133-140.	3.2	11
2	High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer. <i>Journal of Medical Genetics</i> , 2022, 59, 115-121.	3.2	13
3	Extended gene panel testing in lobular breast cancer. <i>Familial Cancer</i> , 2022, 21, 129-136.	1.9	1
4	Patient reported outcome measures in a cohort of patients at high risk of breast cancer treated by bilateral risk reducing mastectomy and breast reconstruction. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2022, 75, 69-76.	1.0	9
5	The importance of ethnicity: Are breast cancer polygenic risk scores ready for women who are not of White European origin?. <i>International Journal of Cancer</i> , 2022, 150, 73-79.	5.1	24
6	The impact of China's R&D subsidies on R&D investment, technological upgrading and economic growth. <i>Technological Forecasting and Social Change</i> , 2022, 174, 121212.	11.6	75
7	Rare germline copy number variants (CNVs) and breast cancer risk. <i>Communications Biology</i> , 2022, 5, 65.	4.4	6
8	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. <i>Breast Cancer Research</i> , 2022, 24, 2.	5.0	15
9	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. <i>JAMA Oncology</i> , 2022, 8, e216744.	7.1	51
10	Code of practice needed for samples donated by trial participants. <i>Lancet Oncology</i> , The, 2022, 23, e89-e90.	10.7	4
11	Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer. <i>British Journal of Cancer</i> , 2022, 126, 1157-1167.	6.4	7
12	Breast cancer risk stratification in women of screening age: Incremental effects of adding mammographic density, polygenic risk, and a gene panel. <i>Genetics in Medicine</i> , 2022, 24, 1485-1494.	2.4	23
13	Does receiving high or low breast cancer risk estimates produce a reduction in subsequent breast cancer screening attendance? Cohort study. <i>Breast</i> , 2022, 64, 47-49.	2.2	5
14	Breast cancer risks associated with missense variants in breast cancer susceptibility genes. <i>Genome Medicine</i> , 2022, 14, 51.	8.2	19
15	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2021, 113, 329-337.	6.3	45
16	Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial. <i>British Journal of Cancer</i> , 2021, 124, 1373-1378.	6.4	3
17	The Angelina Jolie effect: Contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer. <i>Scientific Reports</i> , 2021, 11, 2847.	3.3	20
18	Breast Cancer Risk Genes " Association Analysis in More than 113,000 Women. <i>New England Journal of Medicine</i> , 2021, 384, 428-439.	27.0	532

#	ARTICLE	IF	CITATIONS
19	The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 215-223.	2.5	10
20	Extending screening intervals for women at low risk of breast cancer: do they find it acceptable?. <i>BMC Cancer</i> , 2021, 21, 637.	2.6	15
21	Is Breast Cancer Risk Associated with Menopausal Hormone Therapy Modified by Current or Early Adulthood BMI or Age of First Pregnancy?. <i>Cancers</i> , 2021, 13, 2710.	3.7	2
22	Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer. <i>Genetics in Medicine</i> , 2021, 23, 1969-1976.	2.4	8
23	The Relationship between Body Mass Index and Mammographic Density during a Premenopausal Weight Loss Intervention Study. <i>Cancers</i> , 2021, 13, 3245.	3.7	5
24	Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 677-687.	2.5	7
25	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. <i>Breast Cancer Research</i> , 2021, 23, 86.	5.0	7
26	Gene Panel Testing for Breast Cancer Reveals Differential Effect of Prior BRCA1/2 Probability. <i>Cancers</i> , 2021, 13, 4154.	3.7	5
27	Uptake of bilateral-risk-reducing-mastectomy: Prospective analysis of 7195 women at high-risk of breast cancer. <i>Breast</i> , 2021, 60, 45-52.	2.2	9
28	Introducing a low-risk breast screening pathway into the NHS Breast Screening Programme: Views from healthcare professionals who are delivering risk-stratified screening. <i>Women's Health</i> , 2021, 17, 174550652110097.	1.5	13
29	Testing a breast cancer prevention and a multiple disease prevention weight loss programme amongst women within the UK NHS breast screening programme—a randomised feasibility study. <i>Pilot and Feasibility Studies</i> , 2021, 7, 220.	1.2	6
30	Agglomeration, absorptive capacity and knowledge governance: implications for public-private firm innovation in China. <i>Regional Studies</i> , 2020, 54, 1069-1083.	4.4	35
31	A case-control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density. <i>International Journal of Cancer</i> , 2020, 146, 2122-2129.	5.1	38
32	Minimum wage impacts on Han-minority Workers' wage distribution and inequality in urban china. <i>Journal of Urban Economics</i> , 2020, 115, 103184.	4.4	15
33	Industry relatedness, FDI liberalization and the indigenous innovation process in China. <i>Regional Studies</i> , 2020, 54, 229-243.	4.4	39
34	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	21.4	120
35	Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. <i>Lancet</i> , The, 2020, 395, 117-122.	13.7	128
36	New evidence confirms that reproductive risk factors can be used to stratify breast cancer risks: Implications for a new population screening paradigm. <i>European Journal of Cancer</i> , 2020, 124, 204-206.	2.8	3

#	ARTICLE	IF	CITATIONS
37	Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years. <i>Breast Cancer Research</i> , 2020, 22, 101.	5.0	19
38	Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial. <i>Breast</i> , 2020, 54, 216-221.	2.2	12
39	Risk stratified breast cancer screening: UK healthcare policy decision-making stakeholders' views on a low-risk breast screening pathway. <i>BMC Cancer</i> , 2020, 20, 680.	2.6	27
40	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. <i>American Journal of Human Genetics</i> , 2020, 107, 837-848.	6.2	39
41	Long-Term Evaluation of Women Referred to a Breast Cancer Family History Clinic (Manchester UK) <i>Tj ETQq1 1 0.784314 rgBT /Overlock</i>	3.7	12
42	Heritability of mammographic breast density. <i>Quantitative Imaging in Medicine and Surgery</i> , 2020, 10, 2387-2391.	2.0	4
43	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	21.4	265
44	Picking 'winners' in space: Impact of spatial targeting on firm performance in China. <i>Journal of Regional Science</i> , 2020, 60, 1025-1046.	3.3	5
45	What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420). <i>BMC Cancer</i> , 2020, 20, 570.	2.6	37
46	Young adulthood body mass index, adult weight gain and breast cancer risk: the PROCAS Study (United) <i>Tj ETQq0 0 0 rgBT /Overlock 10</i>	6.4	21
47	Explaining the urban premium in Chinese cities and the role of place-based policies. <i>Environment and Planning A</i> , 2020, 52, 1332-1356.	3.6	6
48	Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (<36 Years) Breast Cancer. <i>Cancers</i> , 2020, 12, 378.	3.7	21
49	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. <i>Nature Communications</i> , 2020, 11, 312.	12.8	30
50	Reply to Comment on 'The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial' <i>British Journal of Cancer</i> , 2020, 122, 925-926.	6.4	0
51	The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial. <i>British Journal of Cancer</i> , 2019, 121, 443-454.	6.4	20
52	Heterogeneous impacts of China's economic and development zone program. <i>Journal of Regional Science</i> , 2019, 59, 797-818.	3.3	27
53	Relatedness economies, absorptive capacity, and economic catch-up: firm-level evidence from China. <i>Industrial and Corporate Change</i> , 2019, , .	2.8	1
54	Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?. <i>Familial Cancer</i> , 2019, 18, 377-379.	1.9	5

#	ARTICLE	IF	CITATIONS
55	Clustering effects on firm exporting with productivity-enhancing R&D in China. <i>World Economy</i> , 2019, 42, 3168-3187.	2.5	2
56	Lifestyle behaviours and health measures of women at increased risk of breast cancer taking chemoprevention. <i>European Journal of Cancer Prevention</i> , 2019, 28, 500-506.	1.3	6
57	Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 141-148.	2.5	56
58	Genome-wide association study of germline variants and breast cancer-specific mortality. <i>British Journal of Cancer</i> , 2019, 120, 647-657.	6.4	52
59	Final Results of the Prospective FH02 Mammographic Surveillance Study of Women Aged 35-39 at Increased Familial Risk of Breast Cancer. <i>EClinicalMedicine</i> , 2019, 7, 39-46.	7.1	7
60	Predictors of weight gain in a cohort of premenopausal early breast cancer patients receiving chemotherapy. <i>Breast</i> , 2019, 45, 1-6.	2.2	21
61	Breast cancer risk status influences uptake, retention and efficacy of a weight loss programme amongst breast cancer screening attendees: two randomised controlled feasibility trials. <i>BMC Cancer</i> , 2019, 19, 1089.	2.6	21
62	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019, 104, 21-34.	6.2	711
63	Ethnic entrepreneurship, initial financing, and business performance in China. <i>Small Business Economics</i> , 2019, 52, 697-712.	6.7	49
64	Intermittent energy restriction for weight loss: Spontaneous reduction of energy intake on unrestricted days. <i>Food Science and Nutrition</i> , 2018, 6, 674-680.	3.4	18
65	Penetrance estimates for BRCA1, BRCA2 (also applied to Lynch syndrome) based on presymptomatic testing: a new unbiased method to assess risk?. <i>Journal of Medical Genetics</i> , 2018, 55, 442-448.	3.2	1
66	Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II. <i>Annals of Oncology</i> , 2018, 29, 504-509.	1.2	21
67	Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction. <i>JAMA Oncology</i> , 2018, 4, 476.	7.1	109
68	Psychosocial issues of a population approach to high genetic risk identification: Behavioural, emotional and informed choice issues. <i>Breast</i> , 2018, 37, 148-153.	2.2	17
69	Personalized prevention in high risk individuals: Managing hormones and beyond. <i>Breast</i> , 2018, 39, 139-147.	2.2	18
70	Agglomeration, (un)related variety and new firm survival in China: Do local subsidies matter?. <i>Papers in Regional Science</i> , 2018, 97, 485-501.	1.9	52
71	Recruitment to the "Breast" Activity and Healthy Eating After Diagnosis (B-AHEAD) Randomized Controlled Trial. <i>Integrative Cancer Therapies</i> , 2018, 17, 131-137.	2.0	9
72	RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 58-66.	2.5	3

#	ARTICLE	IF	CITATIONS
73	Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 779-785.	2.5	9
74	“For me it's about not feeling like I'm on a diet”: a thematic analysis of women's experiences of an intermittent energy restricted diet to reduce breast cancer risk. <i>Journal of Human Nutrition and Dietetics</i> , 2018, 31, 773-780.	2.5	8
75	White Blood Cell <i><i>BRCA1</i></i> Promoter Methylation Status and Ovarian Cancer Risk. <i>Annals of Internal Medicine</i> , 2018, 168, 326.	3.9	37
76	Breast cancer risk in a screening cohort of Asian and white British/Irish women from Manchester UK. <i>BMC Public Health</i> , 2018, 18, 178.	2.9	18
77	Psychological impact of providing women with personalised 10-year breast cancer risk estimates. <i>British Journal of Cancer</i> , 2018, 118, 1648-1657.	6.4	41
78	Reader performance in visual assessment of breast density using visual analogue scales: are some readers more predictive of breast cancer?. , 2018, , .		0
79	Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 743-750.	1.6	58
80	The impact of using weight estimated from mammographic images vs. self-reported weight on breast cancer risk calculation. <i>Proceedings of SPIE</i> , 2017, 10134, .	0.8	0
81	The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study. <i>Journal of Medical Genetics</i> , 2017, 54, 111-113.	3.2	56
82	Impacts of Migration and Remittances on Ethnic Income Inequality in Rural China. <i>World Development</i> , 2017, 94, 200-211.	4.9	73
83	Picking “winners” in China: Do subsidies matter for indigenous innovation and firm productivity?. <i>China Economic Review</i> , 2017, 44, 154-165.	4.4	110
84	Visual assessment of breast density using Visual Analogue Scales: observer variability, reader attributes and reading time. , 2017, , .		3
85	Marshallian Sources of Relatedness and Their Effects on Firm Survival and Subsequent Success in China. <i>Economic Geography</i> , 2017, 93, 346-366.	4.6	19
86	False-negative MRI breast screening in high-risk women. <i>Clinical Radiology</i> , 2017, 72, 207-216.	1.1	17
87	A randomised trial of screening with digital breast tomosynthesis plus conventional digital 2D mammography versus 2D mammography alone in younger higher risk women. <i>European Journal of Radiology</i> , 2017, 94, 133-139.	2.6	8
88	Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores. <i>Familial Cancer</i> , 2017, 16, 173-179.	1.9	2
89	Potential Benefits and Harms of Intermittent Energy Restriction and Intermittent Fasting Amongst Obese, Overweight and Normal Weight Subjects” A Narrative Review of Human and Animal Evidence. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2017, 7, 4.	2.1	100
90	Identifying the Sources of Agglomeration Benefits within China's Economic and Development Zones. <i>SSRN Electronic Journal</i> , 2017, , .	0.4	1

#	ARTICLE	IF	CITATIONS
91	Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I). <i>Journal of Clinical Oncology</i> , 2017, 35, 2666-2673.	1.6	40
92	Do Marshallian Sources Drive Technological Relatedness? Implications for Firm Survival And Subsequent Success in China. <i>SSRN Electronic Journal</i> , 2016, , .	0.4	4
93	Impacts of Migration and Remittances on Ethnic Income Inequality in Rural China. <i>SSRN Electronic Journal</i> , 2016, , .	0.4	1
94	Marshallian Sources of Relatedness, Technological Capabilities and Firm Productivity in China. <i>SSRN Electronic Journal</i> , 2016, , .	0.4	5
95	How to Manage the Obese Patient With Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 4284-4294.	1.6	45
96	Breast cancer risk feedback to women in the UK NHS breast screening population. <i>British Journal of Cancer</i> , 2016, 114, 1045-1052.	6.4	73
97	Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 591-596.	2.5	5
98	Firm R&D, innovation and easing financial constraints in China: Does corporate tax reform matter?. <i>Research Policy</i> , 2016, 45, 1996-2007.	6.4	159
99	Intermittent energy restriction induces changes in breast gene expression and systemic metabolism. <i>Breast Cancer Research</i> , 2016, 18, 57.	5.0	37
100	Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality. <i>Hereditary Cancer in Clinical Practice</i> , 2016, 14, 8.	1.5	47
101	Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. <i>Lancet</i> , The, 2016, 387, 866-873.	13.7	149
102	No strong evidence for increased risk of breast cancer 8â€“26 years after multiple mammograms in their 30s in females at moderate and high familial risk. <i>British Journal of Radiology</i> , 2016, 89, 20150960.	2.2	2
103	Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 597-601.	2.5	29
104	Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 139-143.	1.6	30
105	Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study. <i>Programme Grants for Applied Research</i> , 2016, 4, 1-210.	1.0	75
106	Mammographic Density Over Time in Women With and Without Breast Cancer. <i>Lecture Notes in Computer Science</i> , 2016, , 291-298.	1.3	1
107	Challenges and Opportunities in the Implementation of Risk-Based Screening for Breast Cancer. , 2016, , 165-187.		0
108	Should We Adjust Visually Assessed Mammographic Density for Observer Variability?. <i>Lecture Notes in Computer Science</i> , 2016, , 540-547.	1.3	0

#	ARTICLE	IF	CITATIONS
109	A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition. <i>European Journal of Cancer</i> , 2015, 51, 2725-2731.	2.8	15
110	Can the breast screening appointment be used to provide risk assessment and prevention advice?. <i>Breast Cancer Research</i> , 2015, 17, 84.	5.0	30
111	Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort. <i>Breast Cancer Research</i> , 2015, 17, 147.	5.0	186
112	Longer term effects of the Angelina Jolie effect: increased risk-reducing mastectomy rates in BRCA carriers and other high-risk women. <i>Breast Cancer Research</i> , 2015, 17, 143.	5.0	77
113	Can Diet and Lifestyle Prevent Breast Cancer: What Is the Evidence?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e66-e73.	3.8	75
114	Tumour characteristics and survival in familial breast cancer prospectively diagnosed by annual mammography. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 87-94.	2.5	2
115	Local mammographic density as a predictor of breast cancer. <i>Proceedings of SPIE</i> , 2015, , .	0.8	2
116	Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2763-2770.	7.0	36
117	Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. <i>Lancet Oncology</i> , The, 2015, 16, 67-75.	10.7	349
118	Beliefs about weight and breast cancer: an interview study with high risk women following a 12-month weight loss intervention. <i>Hereditary Cancer in Clinical Practice</i> , 2015, 13, 1.	1.5	25
119	Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis. <i>Familial Cancer</i> , 2015, 14, 531-538.	1.9	45
120	Indigenous innovation with heterogeneous risk and new firm survival in a transitioning Chinese economy. <i>Research Policy</i> , 2015, 44, 1866-1876.	6.4	58
121	Targeting tumor-initiating cells: Eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction. <i>Oncotarget</i> , 2015, 6, 4585-4601.	1.8	55
122	Fulvestrant. , 2015, , 1795-1799.		0
123	JNK1 stress signaling is hyper-activated in high breast density and the tumor stroma: Connecting fibrosis, inflammation, and stemness for cancer prevention. <i>Cell Cycle</i> , 2014, 13, 580-599.	2.6	52
124	Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I. <i>Breast Cancer Research</i> , 2014, 16, 451.	5.0	74
125	Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. <i>British Journal of Cancer</i> , 2014, 110, 1681-1687.	6.4	77
126	Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 1460-1468.	10.7	56

#	ARTICLE	IF	CITATIONS
127	Breast Cancer Risk in Young Women in the National Breast Screening Programme: Implications for Applying NICE Guidelines for Additional Screening and Chemoprevention. <i>Cancer Prevention Research</i> , 2014, 7, 993-1001.	1.5	37
128	Mammographic surveillance in women aged 35-39 at enhanced familial risk of breast cancer (FH02). <i>Familial Cancer</i> , 2014, 13, 13-21.	1.9	13
129	MRI breast screening in high-risk women: cancer detection and survival analysis. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 663-672.	2.5	133
130	Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2014, 383, 1041-1048.	13.7	504
131	Breast cancer risk assessment in 8,824 women attending a family history evaluation and screening programme. <i>Familial Cancer</i> , 2014, 13, 189-196.	1.9	22
132	Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies. <i>Journal of Medical Genetics</i> , 2014, 51, 573-580.	3.2	15
133	Risk determination and prevention of breast cancer. <i>Breast Cancer Research</i> , 2014, 16, 446.	5.0	248
134	CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 216-227.	4.7	150
135	The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. <i>Breast Cancer Research</i> , 2014, 16, 442.	5.0	252
136	Use of Volumetric Breast Density Measures for the Prediction of Weight and Body Mass Index. <i>Lecture Notes in Computer Science</i> , 2014, , 282-289.	1.3	2
137	Contralateral breast cancer risk in BRCA1/2-positive families needs to be adjusted for phenocopy rates particularly in second-degree untested relatives. <i>Breast Cancer Research</i> , 2013, 15, 401.	5.0	1
138	Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 135-142.	2.5	144
139	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R92.	5.0	320
140	Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 611-618.	2.5	58
141	PB.17: Inter-observer agreement in visual analogue scale assessment of percentage breast density. <i>Breast Cancer Research</i> , 2013, 15, .	5.0	3
142	The effect of intermittent energy and carbohydrate restriction vs. daily energy restriction on weight loss and metabolic disease risk markers in overweight women. <i>British Journal of Nutrition</i> , 2013, 110, 1534-1547.	2.3	336
143	Reverse Warburg Effect in a Patient With Aggressive B-Cell Lymphoma: Is Lactic Acidosis a Paraneoplastic Syndrome?. <i>Seminars in Oncology</i> , 2013, 40, 403-418.	2.2	40
144	Breast cancer prevention: SERMs come of age. <i>Lancet, The</i> , 2013, 381, 1795-1797.	13.7	6

#	ARTICLE	IF	CITATIONS
145	Creating a tumor-resistant microenvironment: Cell-mediated delivery of TNF α completely prevents breast cancer tumor formation in vivo. <i>Cell Cycle</i> , 2013, 12, 480-490.	2.6	26
146	Increased Rate of Phenocopies in All Age Groups in <i>BRCA1</i> / <i>BRCA2</i> Mutation Kindred, but Increased Prospective Breast Cancer Risk Is Confined to <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 2269-2276.	2.5	13
147	Cigarette smoke metabolically promotes cancer, via autophagy and premature aging in the host stromal microenvironment. <i>Cell Cycle</i> , 2013, 12, 818-825.	2.6	51
148	Ovarian cancer among 8005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for <i>BRCA1</i> and <i>BRCA2</i> . <i>Journal of Medical Genetics</i> , 2013, 50, 368-372.	3.2	23
149	Ethanol exposure induces the cancer-associated fibroblast phenotype and lethal tumor metabolism. <i>Cell Cycle</i> , 2013, 12, 289-301.	2.6	43
150	Carbonic anhydrase 9 (CA9) and redox signaling in cancer-associated fibroblasts: Therapeutic implications. <i>Cell Cycle</i> , 2013, 12, 2534-2534.	2.6	3
151	Stromal glycolysis and MCT4 are hallmarks of DCIS progression to invasive breast cancer. <i>Cell Cycle</i> , 2013, 12, 2935-2936.	2.6	11
152	Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment. <i>Cell Cycle</i> , 2013, 12, 2580-2597.	2.6	75
153	Mitochondrial dysfunction in breast cancer cells prevents tumor growth. <i>Cell Cycle</i> , 2013, 12, 172-182.	2.6	76
154	Same task, same observers, different values: the problem with visual assessment of breast density. , 2013, , .		4
155	CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis. <i>Cell Cycle</i> , 2012, 11, 3599-3610.	2.6	182
156	Are We Ready for Online Tools in Decision Making for <i>BRCA1/2</i> Mutation Carriers?. <i>Journal of Clinical Oncology</i> , 2012, 30, 471-473.	1.6	9
157	Detection and management of women at increased risk of breast cancer. <i>Clinical Practice (London, England)</i> 11(1):078-081	0.1	0
158	Ketone body utilization drives tumor growth and metastasis. <i>Cell Cycle</i> , 2012, 11, 3964-3971.	2.6	152
159	Metabolic reprogramming and two-compartment tumor metabolism. <i>Cell Cycle</i> , 2012, 11, 3280-3289.	2.6	77
160	Metabolic remodeling of the tumor microenvironment: Migration stimulating factor (MSF) reprograms myofibroblasts toward lactate production, fueling anabolic tumor growth. <i>Cell Cycle</i> , 2012, 11, 3403-3414.	2.6	42
161	Two-compartment tumor metabolism: Autophagy in the tumor microenvironment and oxidative mitochondrial metabolism (OXPHOS) in cancer cells. <i>Cell Cycle</i> , 2012, 11, 2545-2559.	2.6	107
162	CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. <i>Cell Cycle</i> , 2012, 11, 2272-2284.	2.6	116

#	ARTICLE	IF	CITATIONS
163	BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment. <i>Cell Cycle</i> , 2012, 11, 4402-4413.	2.6	71
164	Breast Cancer Risk for Noncarriers of Family-Specific <i>BRCA1</i> and <i>BRCA2</i> Mutations: More Trouble With Phenocopies. <i>Journal of Clinical Oncology</i> , 2012, 30, 1142-1143.	1.6	5
165	Is cancer a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism. <i>Cell Cycle</i> , 2012, 11, 253-263.	2.6	57
166	Genesis and Outcome of a Breast Cancer Trial to Develop the Aromatase Inhibitor Anastrozole. <i>Clinical Chemistry</i> , 2012, 58, 782-783.	3.2	1
167	Hereditary ovarian cancer and two-compartment tumor metabolism. <i>Cell Cycle</i> , 2012, 11, 4152-4166.	2.6	53
168	Mitochondria fuel breast cancer metabolism: Fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells. <i>Cell Cycle</i> , 2012, 11, 4390-4401.	2.6	147
169	Ketone bodies and two-compartment tumor metabolism: Stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells. <i>Cell Cycle</i> , 2012, 11, 3956-3963.	2.6	103
170	Warburg Meets Autophagy: Cancer-Associated Fibroblasts Accelerate Tumor Growth and Metastasis via Oxidative Stress, Mitophagy, and Aerobic Glycolysis. <i>Antioxidants and Redox Signaling</i> , 2012, 16, 1264-1284.	5.4	254
171	Oestrogen and breast cancer: results from the WHI trial. <i>Lancet Oncology</i> , The, 2012, 13, 437-438.	10.7	74
172	Prevention of breast cancer in the context of a national breast screening programme. <i>Journal of Internal Medicine</i> , 2012, 271, 321-330.	6.0	31
173	Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. <i>Breast Cancer Research</i> , 2012, 14, R57.	5.0	75
174	Surgical treatment decisions for older patients: The influence of tumour characteristics, patient health and choice. <i>Journal of Geriatric Oncology</i> , 2012, 3, S19-S20.	1.0	0
175	Assessing Individual Breast Cancer Risk within the U.K. National Health Service Breast Screening Program: A New Paradigm for Cancer Prevention. <i>Cancer Prevention Research</i> , 2012, 5, 943-951.	1.5	104
176	Metabolic reprogramming of cancer-associated fibroblasts by TGF- β 2 drives tumor growth: Connecting TGF- β 2 signaling with Warburg-like cancer metabolism and L-lactate production. <i>Cell Cycle</i> , 2012, 11, 3019-3035.	2.6	249
177	Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2012, 38, 318-328.	7.7	77
178	Energy restriction and the prevention of breast cancer. <i>Proceedings of the Nutrition Society</i> , 2012, 71, 263-275.	1.0	33
179	The milk protein β -casein functions as a tumor suppressor via activation of STAT1 signaling, effectively preventing breast cancer tumor growth and metastasis. <i>Cell Cycle</i> , 2012, 11, 3972-3982.	2.6	31
180	Mitochondrial metabolism in cancer metastasis. <i>Cell Cycle</i> , 2012, 11, 1445-1454.	2.6	162

#	ARTICLE	IF	CITATIONS
181	Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance. <i>Cell Cycle</i> , 2012, 11, 4174-4180.	2.6	105
182	Downregulation of stromal BRCA1 drives breast cancer tumor growth via upregulation of HIF-1 α , autophagy and ketone body production. <i>Cell Cycle</i> , 2012, 11, 4167-4173.	2.6	40
183	Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial. <i>British Journal of Cancer</i> , 2012, 107, 230-233.	6.4	18
184	Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: Further evidence of benefit. <i>International Journal of Cancer</i> , 2012, 131, 417-425.	5.1	23
185	Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis, via glycolysis and ketone production. <i>Cell Cycle</i> , 2012, 11, 2285-2302.	2.6	209
186	Caveolin-1 and Cancer Metabolism in the Tumor Microenvironment: Markers, Models, and Mechanisms. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2012, 7, 423-467.	22.4	249
187	Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 727-734.	2.5	47
188	Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 625-629.	2.5	30
189	Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1191-1198.	2.5	36
190	Volumetric and Area-Based Breast Density Measurement in the Predicting Risk of Cancer at Screening (PROCAS) Study. <i>Lecture Notes in Computer Science</i> , 2012, , 228-235.	1.3	6
191	Mitochondrial Fission Induces Glycolytic Reprogramming in Cancer-Associated Myofibroblasts, Driving Stromal Lactate Production, and Early Tumor Growth. <i>Oncotarget</i> , 2012, 3, 798-810.	1.8	112
192	Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4273-4278.	1.6	666
193	Cytokine production and inflammation drive autophagy in the tumor microenvironment. <i>Cell Cycle</i> , 2011, 10, 1784-1793.	2.6	137
194	Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. <i>Journal of Medical Genetics</i> , 2011, 48, 520-522.	3.2	69
195	Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis. <i>Cell Cycle</i> , 2011, 10, 2440-2449.	2.6	208
196	Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. <i>Cancer Biology and Therapy</i> , 2011, 12, 924-938.	3.4	154
197	Migration and Inequality in Xinjiang: A Survey of Han and Uyghur Migrants in Urumqi. <i>Eurasian Geography and Economics</i> , 2011, 52, 119-139.	2.6	84
198	Stromal epithelial metabolic coupling in cancer: Integrating autophagy and metabolism in the tumor microenvironment. <i>International Journal of Biochemistry and Cell Biology</i> , 2011, 43, 1045-1051.	2.8	218

#	ARTICLE	IF	CITATIONS
199	Preventive therapy for breast cancer: a consensus statement. <i>Lancet Oncology</i> , The, 2011, 12, 496-503.	10.7	196
200	10-year analysis of the ATAC trial: wrong conclusion? Authors' reply. <i>Lancet Oncology</i> , The, 2011, 12, 217.	10.7	2
201	Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. <i>Breast Cancer Research</i> , 2011, 13, 213.	5.0	153
202	Influence of Comorbidities and Age on Risk of Death Without Recurrence: A Retrospective Analysis of the Arimidex, Tamoxifen Alone or in Combination Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 4266-4272.	1.6	61
203	Labor Market Segmentation in Urumqi, Xinjiang: Exposing Labor Market Segments and Testing the Relationship between Migration and Segmentation. <i>Growth and Change</i> , 2011, 42, 200-226.	2.6	23
204	Fulvestrant Revisited: Efficacy and Safety of the 500-mg Dose. <i>Clinical Breast Cancer</i> , 2011, 11, 204-210.	2.4	38
205	Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect. <i>Cell Cycle</i> , 2011, 10, 2504-2520.	2.6	245
206	Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 279-287.	2.5	80
207	Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth. <i>Cancer Biology and Therapy</i> , 2011, 12, 1101-1113.	3.4	99
208	Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ. <i>Cell Cycle</i> , 2011, 10, 4047-4064.	2.6	256
209	Mitochondrial oxidative stress in cancer-associated fibroblasts drives lactate production, promoting breast cancer tumor growth. <i>Cell Cycle</i> , 2011, 10, 4065-4073.	2.6	110
210	Accelerated aging in the tumor microenvironment. <i>Cell Cycle</i> , 2011, 10, 2059-2063.	2.6	63
211	The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. <i>International Journal of Obesity</i> , 2011, 35, 714-727.	3.4	573
212	Ketones and lactate increase cancer cell stemness, driving recurrence, metastasis and poor clinical outcome in breast cancer. <i>Cell Cycle</i> , 2011, 10, 1271-1286.	2.6	295
213	Evidence for a stromal-epithelial lactate shuttle in human tumors. <i>Cell Cycle</i> , 2011, 10, 1772-1783.	2.6	393
214	Understanding the metabolic basis of drug resistance. <i>Cell Cycle</i> , 2011, 10, 2521-2528.	2.6	97
215	Matrix remodeling stimulates stromal autophagy, fueling cancer cell mitochondrial metabolism and metastasis. <i>Cell Cycle</i> , 2011, 10, 2021-2034.	2.6	69
216	Defining bad stroma in human breast tumors. <i>Cell Cycle</i> , 2011, 10, 3056-3056.	2.6	1

#	ARTICLE	IF	CITATIONS
217	Energy transfer in "parasitic" cancer metabolism. <i>Cell Cycle</i> , 2011, 10, 4208-4216.	2.6	144
218	Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. <i>British Journal of Cancer</i> , 2011, 105, 22-27.	6.4	60
219	Tamoxifen-Induced Reduction in Mammographic Density and Breast Cancer Risk Reduction: A Nested Case-Control Study. <i>Journal of the National Cancer Institute</i> , 2011, 103, 744-752.	6.3	358
220	Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment. <i>Cancer Biology and Therapy</i> , 2011, 11, 383-394.	3.4	122
221	Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells. <i>Cancer Biology and Therapy</i> , 2011, 12, 1085-1097.	3.4	145
222	Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. <i>Annals of Oncology</i> , 2011, 22, 857-862.	1.2	76
223	Fulvestrant. , 2011, , 1459-1463.		0
224	Significant differences in UK and US female bone density reference ranges. <i>Osteoporosis International</i> , 2010, 21, 1871-1880.	3.1	18
225	RASSF1A polymorphism in familial breast cancer. <i>Familial Cancer</i> , 2010, 9, 263-265.	1.9	19
226	Breast cancer susceptibility variants alter risk in familial ovarian cancer. <i>Familial Cancer</i> , 2010, 9, 503-506.	1.9	4
227	Can metabolomics in addition to genomics add to prognostic and predictive information in breast cancer?. <i>BMC Medicine</i> , 2010, 8, 73.	5.5	4
228	Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status. <i>British Journal of Cancer</i> , 2010, 102, 1091-1098.	6.4	42
229	Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: Evidence for stromal-epithelial metabolic coupling. <i>Cell Cycle</i> , 2010, 9, 2412-2422.	2.6	130
230	Understanding the "lethal" drivers of tumor-stroma co-evolution. <i>Cancer Biology and Therapy</i> , 2010, 10, 537-542.	3.4	180
231	Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 1829-1834.	1.6	647
232	Insights Into the Place of Fulvestrant for the Treatment of Advanced Endocrine Responsive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4548-4550.	1.6	13
233	Ketones and lactate fuel tumor growth and metastasis. <i>Cell Cycle</i> , 2010, 9, 3506-3514.	2.6	526
234	HIF1-alpha functions as a tumor promoter in cancer-associated fibroblasts, and as a tumor suppressor in breast cancer cells. <i>Cell Cycle</i> , 2010, 9, 3534-3551.	2.6	207

#	ARTICLE	IF	CITATIONS
235	Uptake of breast cancer prevention and screening trials. <i>Journal of Medical Genetics</i> , 2010, 47, 853-855.	3.2	16
236	Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: Implications for breast cancer and DCIS therapy with autophagy inhibitors. <i>Cell Cycle</i> , 2010, 9, 2423-2433.	2.6	238
237	The autophagic tumor stroma model of cancer or "battery-operated tumor growth". <i>Cell Cycle</i> , 2010, 9, 4297-4306.	2.6	165
238	Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution. <i>Cell Cycle</i> , 2010, 9, 3276-3296.	2.6	400
239	Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 3411-3415.	1.6	271
240	Breast cancer susceptibility variants alter risks in familial disease. <i>Journal of Medical Genetics</i> , 2010, 47, 126-131.	3.2	35
241	Autophagy in cancer associated fibroblasts promotes tumor cell survival. <i>Cell Cycle</i> , 2010, 9, 3515-3533.	2.6	377
242	Hormone Replacement Therapy and Breast Cancer. <i>Recent Results in Cancer Research</i> , 2010, 188, 115-124.	1.8	22
243	The autophagic tumor stroma model of cancer. <i>Cell Cycle</i> , 2010, 9, 3485-3505.	2.6	248
244	Lung cancer after treatment for breast cancer. <i>Lancet Oncology</i> , The, 2010, 11, 1184-1192.	10.7	30
245	Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. <i>Lancet Oncology</i> , The, 2010, 11, 1135-1141.	10.7	1,017
246	The emerging breast cancer epidemic: early diagnosis and treatment. <i>Breast Cancer Research</i> , 2010, 12, S10.	5.0	21
247	Transcriptional evidence for the "Reverse Warburg Effect" in human breast cancer tumor stroma and metastasis: Similarities with oxidative stress, inflammation, Alzheimer's disease, and "Neuron-Glia Metabolic Coupling". <i>Aging</i> , 2010, 2, 185-199.	3.1	136
248	Endocrine Therapy. , 2010, , 329-352.		0
249	Uptake of Risk-Reducing Surgery in Unaffected Women at High Risk of Breast and Ovarian Cancer Is Risk, Age, and Time Dependent. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2318-2324.	2.5	132
250	Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. <i>Journal of Medical Genetics</i> , 2009, 46, 811-817.	3.2	80
251	Normal Breast Tissue Implanted into Athymic Nude Mice Identifies Biomarkers of the Effects of Human Pregnancy Levels of Estrogen. <i>Cancer Prevention Research</i> , 2009, 2, 257-264.	1.5	8
252	Biomarkers of Dietary Energy Restriction in Women at Increased Risk of Breast Cancer. <i>Cancer Prevention Research</i> , 2009, 2, 720-731.	1.5	41

#	ARTICLE	IF	CITATIONS
253	A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial. American Journal of Obstetrics and Gynecology, 2009, 200, 80.e1-80.e7.	1.3	19
254	Energy Restriction for Breast Cancer Prevention. Recent Results in Cancer Research, 2009, 181, 97-111.	1.8	27
255	Breast tumour stroma is a prognostic indicator and target for therapy. Breast Cancer Research, 2009, 11, S16.	5.0	16
256	Risk reducing mastectomy: outcomes in 10 European centres. Journal of Medical Genetics, 2009, 46, 254-258.	3.2	80
257	Prognostic Value of a Combined ER, PgR, Ki67, HER2 Immunohistochemical (IHC4) Score and Comparison with the GHI Recurrence Score – Results from TransATAC.. Cancer Research, 2009, 69, 74-74.	0.9	41
258	The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets – improving meta-analysis and prediction of prognosis. BMC Medical Genomics, 2008, 1, 42.	1.5	134
259	Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer, 2008, 8, 155.	2.6	191
260	The endocrine prevention of breast cancer. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 615-623.	4.7	38
261	Should lifestyle modifications be promoted to prevent breast cancer?. Breast Cancer Research, 2008, 10, S11.	5.0	2
262	The effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: a randomised pilot trial. Breast Cancer Research, 2008, 10, .	5.0	0
263	Adherence to hormone therapy in a chemoprevention randomised trial. Breast Cancer Research, 2008, 10, .	5.0	0
264	Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Research, 2008, 10, R26.	5.0	88
265	Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group. Cancer Treatment Reviews, 2008, 34, S3-S18.	7.7	209
266	Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncology, The, 2008, 9, 45-53.	10.7	929
267	Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncology, The, 2008, 9, 953-961.	10.7	108
268	Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230. Journal of Clinical Oncology, 2008, 26, 1051-1057.	1.6	363
269	Better Life Expectancy in Women with <i>BRCA2</i> Compared with <i>BRCA1</i> Mutations Is Attributable to Lower Frequency and Later Onset of Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1535-1542.	2.5	15
270	Response and Resistance to the Endocrine Prevention of Breast Cancer. Advances in Experimental Medicine and Biology, 2008, 617, 201-211.	1.6	10

#	ARTICLE	IF	CITATIONS
271	The Origin of Estrogen Receptor $\hat{\pm}$ -Positive and $\hat{\pm}$ -Negative Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2008, 617, 79-86.	1.6	1
272	Clinical studies with anastrozole. , 2008, , 101-125.		0
273	Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. <i>Endocrine-Related Cancer</i> , 2007, 14, 169-187.	3.1	165
274	Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer--96-Month Follow-up of the Randomized IBIS-I Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 272-282.	6.3	510
275	The effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides. <i>Growth Hormone and IGF Research</i> , 2007, 17, 210-219.	1.1	6
276	Breast cancer risk-assessment models. <i>Breast Cancer Research</i> , 2007, 9, 213.	5.0	142
277	Metabolic approaches to breast cancer treatment and prevention. <i>Breast Cancer Research</i> , 2007, 9, .	5.0	1
278	Origins of breast cancer subtypes and therapeutic implications. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 516-525.	4.3	155
279	TPD52 and NFKB1 gene expression levels correlate with G2 chromosomal radiosensitivity in lymphocytes of women with and at risk of hereditary breast cancer. <i>International Journal of Radiation Biology</i> , 2007, 83, 409-420.	1.8	12
280	Older women with operable breast cancer are less likely to have surgery. <i>British Journal of Surgery</i> , 2007, 94, 1209-1215.	0.3	61
281	Surveillance for familial breast cancer: Differences in outcome according toBRCA mutation status. <i>International Journal of Cancer</i> , 2007, 121, 1017-1020.	5.1	86
282	Non-standard management of breast cancer increases with age in the UK: a population based cohort of women $\hat{\text{a}}\hat{\text{c}}\hat{\text{3}}\hat{\text{4}}\hat{\text{6}}\hat{\text{5}}$ years. <i>British Journal of Cancer</i> , 2007, 96, 1197-1203.	6.4	106
283	Cyclin-dependent kinase inhibitors and basement membrane interact to regulate breast epithelial cell differentiation and acinar morphogenesis. <i>Cell Proliferation</i> , 2007, 40, 721-740.	5.3	11
284	Adult weight gain and central obesity in women with and without a family history of breast cancer: a case control study. <i>Familial Cancer</i> , 2007, 6, 287-294.	1.9	13
285	Estrogen Deprivation for Breast Cancer Prevention. <i>Recent Results in Cancer Research</i> , 2007, 174, 151-167.	1.8	7
286	Optimal use of aromatase inhibitors for adjuvant treatment of hormone-sensitive early breast cancer: Up front or sequenced after tamoxifen?. <i>Journal of Clinical Oncology</i> , 2007, 25, 541-541.	1.6	2
287	Effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: a randomised pilot trial. <i>Breast Cancer Research</i> , 2006, 8, 1.	5.0	1
288	High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?. <i>Breast Cancer Research</i> , 2006, 8, 214.	5.0	28

#	ARTICLE	IF	CITATIONS
289	Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. <i>Lancet Oncology</i> , The, 2006, 7, 633-643.	10.7	356
290	BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. <i>European Journal of Cancer</i> , 2006, 42, 1143-1150.	2.8	139
291	Screening younger women with a family history of breast cancer " does early detection improve outcome?. <i>European Journal of Cancer</i> , 2006, 42, 1385-1390.	2.8	42
292	The "Arimidex", Tamoxifen, Alone or in Combination (ATAC) Trial: A Step Forward in the Treatment of Early Breast Cancer. <i>Reviews on Recent Clinical Trials</i> , 2006, 1, 207-215.	0.8	9
293	Energy balance adiposity and breast cancer - energy restriction strategies for breast cancer prevention. <i>Obesity Reviews</i> , 2006, 7, 33-47.	6.5	48
294	Is fulvestrant ("Faslodex") just another selective estrogen receptor modulator?. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 521-523.	2.5	7
295	Fulvestrant ("Faslodex™): Current and future role in breast cancer management. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 57, 265-273.	4.4	51
296	Quality of Life of Postmenopausal Women in the ATAC ("Arimidex", Tamoxifen, Alone or in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 4 Cancer Research and Treatment, 2006, 100, 273-284.	2.5	218
297	Late Toxicity Is Not Increased in <i>BRCA1/BRCA2</i> Mutation Carriers Undergoing Breast Radiotherapy in the United Kingdom. <i>Clinical Cancer Research</i> , 2006, 12, 7025-7032.	7.0	75
298	Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. <i>Endocrine-Related Cancer</i> , 2006, 13, 617-628.	3.1	69
299	Re: Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. <i>Journal of the National Cancer Institute</i> , 2006, 98, 643-643.	6.3	9
300	Acute Chemotherapy-Related Toxicity Is Not Increased in BRCA1 and BRCA2 Mutation Carriers Treated for Breast Cancer in the United Kingdom. <i>Clinical Cancer Research</i> , 2006, 12, 7033-7038.	7.0	36
301	Pure oestrogen antagonists for the treatment of advanced breast cancer. <i>Endocrine-Related Cancer</i> , 2006, 13, 689-706.	3.1	100
302	Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. <i>Endocrine-Related Cancer</i> , 2006, 13, 273-278.	3.1	115
303	Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations. <i>British Journal of Cancer</i> , 2006, 94, 1021-1028.	6.4	24
304	Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?. <i>British Journal of Cancer</i> , 2006, 94, 460-464.	6.4	65
305	Automated Breast Tissue Measurement of Women at Increased Risk of Breast Cancer. <i>Lecture Notes in Computer Science</i> , 2006, , 131-136.	1.3	15
306	Selective oestrogen receptor modulators, aromatase inhibitors and the female breast. <i>Current Opinion in Obstetrics and Gynecology</i> , 2005, 17, 429-434.	2.0	1

#	ARTICLE	IF	CITATIONS
307	O6-(4-bromothienyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts. <i>British Journal of Cancer</i> , 2005, 93, 1152-1156.	6.4	52
308	Defining the Roles of Aromatase Inhibitors in the Adjuvant Treatment of Early-Stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 6, 302-309.	2.4	11
309	Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma. <i>Cancer</i> , 2005, 104, 236-239.	4.1	154
310	Retroperitoneal tumour infiltration detected by bone scanning in patients with infiltrating lobular carcinoma of the breast. <i>British Journal of Surgery</i> , 2005, 72, 626-628.	0.3	4
311	Extended role for needle biopsy in the management of carcinoma of the breast. <i>British Journal of Surgery</i> , 2005, 76, 553-558.	0.3	20
312	Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. <i>Breast Cancer Research and Treatment</i> , 2005, 92, 169-174.	2.5	32
313	Association of Gain and Loss of Weight before and after Menopause with Risk of Postmenopausal Breast Cancer in the Iowa Women's Health Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 656-661.	2.5	376
314	Overview of the impact of conventional systemic therapies on breast cancer. <i>Endocrine-Related Cancer</i> , 2005, 12, S9-S16.	3.1	15
315	Energy balance in patients with advanced NSCLC, metastatic melanoma and metastatic breast cancer receiving chemotherapy – a longitudinal study. <i>British Journal of Cancer</i> , 2005, 92, 673-680.	6.4	42
316	Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. <i>Lancet, The</i> , 2005, 365, 60-62.	13.7	2,078
317	Preventing cancer, cardiovascular disease, and diabetes. <i>Lancet, The</i> , 2005, 365, 1449-1451.	13.7	36
318	Adjuvant aromatase inhibitors for breast cancer. <i>Lancet, The</i> , 2005, 366, 431-433.	13.7	31
319	ATAC trial update. <i>Lancet, The</i> , 2005, 365, 1225-1226.	13.7	467
320	Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. <i>Lancet Oncology, The</i> , 2005, 6, 773-779.	10.7	103
321	Are aromatase inhibitors superior to antiestrogens?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2005, 93, 237-247.	2.5	33
322	Vascular effects of aromatase inhibitors: Data from clinical trials. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2005, 95, 143-149.	2.5	42
323	The future of fulvestrant (Faslodex™). <i>Cancer Treatment Reviews</i> , 2005, 31, S26-S33.	7.7	22
324	Clinical development of fulvestrant (Faslodex™). <i>Cancer Treatment Reviews</i> , 2005, 31, S3-S9.	7.7	23

#	ARTICLE	IF	CITATIONS
325	Surgical decisions made by 158 women with hereditary breast cancer aged <50 years. <i>European Journal of Surgical Oncology</i> , 2005, 31, 1112-1118.	1.0	41
326	A putative human breast stem cell population is enriched for steroid receptor-positive cells. <i>Developmental Biology</i> , 2005, 277, 443-456.	2.0	312
327	New developments in the treatment of postmenopausal breast cancer. <i>Trends in Endocrinology and Metabolism</i> , 2005, 16, 420-428.	7.1	21
328	Anastrozole: A New Gold Standard of Hormonal Treatment for Breast Cancer?. <i>Women's Health</i> , 2005, 1, 309-322.	1.5	2
329	Mechanisms of Disease: prediction and prevention of breast cancer—cellular and molecular interactions. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 635-646.	4.3	29
330	Early stopping of clinical trials. <i>Breast Cancer Research</i> , 2005, 7, 181-3.	5.0	7
331	Effects of oestrogen on gene expression in the epithelium and stroma of the normal human breast. <i>Breast Cancer Research</i> , 2005, 7, 1.	5.0	0
332	The future of breast cancer prevention. <i>Breast Cancer Research</i> , 2005, 7, 1.	5.0	0
333	Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 658-658.	1.6	15
334	Incorporating Weight Control into Management of Patients with Early Breast Cancer in the U.K.. <i>Nutrition and Disease Prevention</i> , 2005, , 535-560.	0.1	0
335	Comparison of Fulvestrant Versus Tamoxifen for the Treatment of Advanced Breast Cancer in Postmenopausal Women Previously Untreated With Endocrine Therapy: A Multinational, Double-Blind, Randomized Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 1605-1613.	1.6	392
336	Quality of Life of Postmenopausal Women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 4261-4271.	1.6	283
337	A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. <i>Journal of Medical Genetics</i> , 2004, 41, 474-480.	3.2	232
338	Energy Balance in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2004, 83, 201-210.	2.5	113
339	A Cancer Research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 53, 341-348.	2.3	25
340	Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. <i>Psycho-Oncology</i> , 2004, 13, 61-66.	2.3	195
341	The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2004, 18, 47-66.	4.7	124
342	Strategies for Managing Breast Cancer Risk After the Menopause. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2004, 3, 289-307.	1.8	3

#	ARTICLE	IF	CITATIONS
343	Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens. <i>Breast Cancer Research</i> , 2004, 6, 269-74.	5.0	49
344	An early peak of relapse after surgery for breast cancer. <i>Breast Cancer Research</i> , 2004, 6, 255-7.	5.0	5
345	Steroid receptors in human breast cancer. <i>Trends in Endocrinology and Metabolism</i> , 2004, 15, 316-323.	7.1	73
346	Spreading the word, but not too thinly. <i>Lancet, The</i> , 2004, 363, 165-166.	13.7	0
347	Adjuvant Use of Anastrozole in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 1524-1526.	1.6	6
348	A Review of the Efficacy of Anastrozole in Postmenopausal Women with Advanced Breast Cancer with Visceral Metastases. <i>Breast Cancer Research and Treatment</i> , 2003, 82, 215-222.	2.5	39
349	New approaches to the endocrine prevention and treatment of breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 39-44.	2.3	29
350	Breast density and breast cancer risk factors in a high-risk population. <i>Breast</i> , 2003, 12, 10-16.	2.2	30
351	Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women. <i>Cancer</i> , 2003, 98, 229-238.	4.1	305
352	Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. <i>Cancer</i> , 2003, 98, 1735-1744.	4.1	836
353	Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. <i>Cancer</i> , 2003, 98, 1802-1810.	4.1	754
354	Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethylnitrosourea combination therapy in patients with advanced breast cancer. <i>International Journal of Cancer</i> , 2003, 103, 686-692.	5.1	5
355	A Roundtable Discussion of Aromatase Inhibitors as Therapy for Breast Cancer. <i>Breast Journal</i> , 2003, 9, 213-222.	1.0	7
356	Regulation of human breast epithelial stem cells. <i>Cell Proliferation</i> , 2003, 36, 45-58.	5.3	109
357	Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?. <i>Breast Cancer Research</i> , 2003, 6, E7.	5.0	19
358	Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. <i>Journal of Medical Genetics</i> , 2003, 40, 807-814.	3.2	261
359	Do Women Understand the Odds? Risk Perceptions and Recall of Risk Information in Women with a Family History of Breast Cancer. <i>Public Health Genomics</i> , 2003, 6, 214-223.	1.0	34
360	Re: Risk-Reduction Mastectomy: Clinical Issues and Research Needs. <i>Journal of the National Cancer Institute</i> , 2002, 94, 307-307.	6.3	4

#	ARTICLE	IF	CITATIONS
361	Management of women with a family history of breast cancer in the North West Region of England: training for implementing a vision of the future. <i>Journal of Medical Genetics</i> , 2002, 39, 531-535.	3.2	9
362	Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine Treatment. <i>Journal of Clinical Oncology</i> , 2002, 20, 3396-3403.	1.6	626
363	Fulvestrant (Faslodex [®]): current status in the therapy of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2002, 2, 151-160.	2.4	31
364	First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. <i>Lancet, The</i> , 2002, 360, 817-824.	13.7	708
365	Written report of presented lectures: endocrine treatment and prevention of breast and gynaecological cancers. <i>European Journal of Cancer</i> , 2002, 38, 13-14.	2.8	15
366	Selective oestrogen receptor downregulator. <i>European Journal of Cancer</i> , 2002, 38, 61-62.	2.8	4
367	Tamoxifen (Nolvadex [™]): a review. <i>Cancer Treatment Reviews</i> , 2002, 28, 165-180.	7.7	205
368	Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. <i>International Journal of Cancer</i> , 2002, 101, 555-559.	5.1	99
369	Breast cancer: Aromatase inhibitors take on tamoxifen. <i>Nature Medicine</i> , 2002, 8, 1341-1344.	30.7	30
370	A follow-up study of breast and other cancers in families of an unselected series of breast cancer patients. <i>British Journal of Cancer</i> , 2002, 86, 718-722.	6.4	13
371	Heterogeneity of O6-alkylguanine DNA-alkyltransferase expression in human breast tumours. <i>British Journal of Cancer</i> , 2002, 86, 1797-1802.	6.4	15
372	Selective estrogen receptor modulators (SERMs). , 2002, , 45-62.		2
373	Control of Proliferation in the Normal and Neoplastic Breast. , 2002, , 73-91.		0
374	Pharmacokinetics of anastrozole and tamoxifen alone and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the Arimidex [®] and Tamoxifen Alone or in Combination [™] (ATAC) trial. <i>British Journal of Cancer</i> , 2001, 85, 317-324.	6.4	126
375	Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2001, 79, 227-237.	2.5	27
376	Uptake of screening and prevention in women at very high risk of breast cancer. <i>Lancet, The</i> , 2001, 358, 889-890.	13.7	56
377	Tamoxifen for the Prevention of Breast Cancer: Psychosocial Impact on Women Participating in Two Randomized Controlled Trials. <i>Journal of Clinical Oncology</i> , 2001, 19, 1885-1892.	1.6	214
378	Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. <i>Cancer</i> , 2001, 91, 1191-1200.	4.1	494

#	ARTICLE	IF	CITATIONS
379	High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2001, 67, 111-116.	2.5	219
380	The effects of oestrogens and anti-oestrogens on cognition. <i>Breast</i> , 2001, 10, 484-491.	2.2	37
381	Risk perception and cancer worry: an exploratory study of the impact of genetic risk counselling in women with a family history of breast cancer. <i>Journal of Medical Genetics</i> , 2001, 38, 139-139.	3.2	100
382	Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. <i>Clinical Cancer Research</i> , 2001, 7, 2620-35.	7.0	87
383	Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. <i>Cancer Journal (Sudbury, Mass)</i> , 2001, 7, 377-87.	2.0	566
384	Initial results of a study into the effectiveness of breast cancer screening in a population identified to be at high risk. <i>Revue D'Epidemiologie Et De Sante Publique</i> , 2001, 49, 471-5.	0.5	7
385	Preliminary experience with pure antiestrogens. <i>Clinical Cancer Research</i> , 2001, 7, 4369s-4375s; discussion 4411s-4412s.	7.0	15
386	Future use of selective estrogen receptor modulators and aromatase inhibitors. <i>Clinical Cancer Research</i> , 2001, 7, 4402s-4410s; discussion 4411s-4412s.	7.0	10
387	ICI 182,780 (Faslodex?). <i>Cancer</i> , 2000, 89, 817-825.	4.1	365
388	Clinical follow-up after bilateral risk reducing (?prophylactic?) mastectomy: mental health and body image outcomes. <i>Psycho-Oncology</i> , 2000, 9, 462-472.	2.3	121
389	Hormonally-regulated proteins in breast secretions are markers of target organ sensitivity. <i>British Journal of Cancer</i> , 2000, 82, 354-360.	6.4	35
390	Clarification of Anastrozole/Megestrol Acetate Trial Program Design. <i>Journal of Clinical Oncology</i> , 2000, 18, 4109-4109.	1.6	0
391	Tamoxifen versus the newer SERMs: what is the evidence?. <i>Annals of Oncology</i> , 2000, 11, 255-266.	1.2	3
392	Serum Soluble Vascular Cell Adhesion Molecule-1: Role as a Surrogate Marker of Angiogenesis. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1329-1336.	6.3	114
393	A protocol for preventative mastectomy in women with an increased lifetime risk of breast cancer. <i>European Journal of Surgical Oncology</i> , 2000, 26, 711-713.	1.0	35
394	P27KIP1 expression indicates that steroid receptor-positive cells are a non-proliferating, differentiated subpopulation of the normal human breast epithelium. <i>European Journal of Cancer</i> , 2000, 36, 28-29.	2.8	21
395	Faslodex (ICI 182780). <i>European Journal of Cancer</i> , 2000, 36, 87-88.	2.8	72
396	ICI 182,780 (Faslodex,®). <i>Cancer</i> , 2000, 89, 817-825.	4.1	9

#	ARTICLE	IF	CITATIONS
397	Title is missing!. Annals of Oncology, 2000, 11, 255-266.	1.2	4
398	Estrogen Receptor in Mammary Gland Physiology. , 2000, , 1-16.		1
399	Macrophage inflammatory protein 1alpha attenuates the toxic effects of temozolomide in human bone marrow granulocyte-macrophage colony-forming cells. Clinical Cancer Research, 2000, 6, 966-70.	7.0	3
400	The therapeutic potential of novel aromatase inhibitors in breast cancer. Expert Opinion on Investigational Drugs, 1999, 8, 269-279.	4.1	4
401	Two-Week Dietary Soy Supplementation Has an Estrogenic Effect on Normal Premenopausal Breast1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4017-4024.	3.6	194
402	Cost-effectiveness implications of increased survival with anastrozole in the treatment of advanced breast cancer. Journal of Medical Economics, 1999, 2, 33-43.	2.1	11
403	The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. British Journal of Cancer, 1999, 79, 311-315.	6.4	43
404	Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases. British Journal of Cancer, 1999, 80, 1265-1270.	6.4	28
405	Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACTa€B. Breast Cancer Research and Treatment, 1999, 55, 187-197.	2.5	285
406	Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. Breast Cancer Research and Treatment, 1999, 58, 157-162.	2.5	37
407	The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Journal of Cancer, 1999, 35, 47-53.	2.8	86
408	Hormonal Resistance in Breast Cancer. Handbook of Experimental Pharmacology, 1999, , 205-221.	1.8	4
409	Estrogen responsiveness and control of normal human breast proliferation. Journal of Mammary Gland Biology and Neoplasia, 1998, 3, 23-35.	2.7	157
410	Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Cancer, 1998, 83, 1142-1152.	4.1	315
411	Psychological support needs for women at high genetic risk of breast cancer: some preliminary indicators. , 1998, 7, 402-412.		104
412	Effect of early American results on patients in a tamoxifen prevention trial (IBIS). Lancet, The, 1998, 352, 1222.	13.7	11
413	The value of dose intensification of standard chemotherapy for advanced breast cancer using colony-stimulating factors alone. Cancer Treatment Reviews, 1998, 24, 173-184.	7.7	5
414	Screening by mammography, women with a family history of breast cancer. European Journal of Cancer, 1998, 34, 937-940.	2.8	82

#	ARTICLE	IF	CITATIONS
415	Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. <i>American Journal of Clinical Nutrition</i> , 1998, 68, 1431S-1436S.	4.7	206
416	Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. <i>Cancer</i> , 1998, 83, 1142-1152.	4.1	197
417	The Primary Use of Endocrine Therapies. <i>Recent Results in Cancer Research</i> , 1998, 152, 227-244.	1.8	15
418	A Randomized Phase-II Study of BB-10010 (Macrophage Inflammatory Protein- 1 α) in Patients With Advanced Breast Cancer Receiving 5-Fluorouracil, Adriamycin, and Cyclophosphamide Chemotherapy. <i>Blood</i> , 1998, 92, 1532-1540.	1.4	25
419	A Randomized Phase-II Study of BB-10010 (Macrophage Inflammatory Protein- 1 α) in Patients With Advanced Breast Cancer Receiving 5-Fluorouracil, Adriamycin, and Cyclophosphamide Chemotherapy. <i>Blood</i> , 1998, 92, 1532-1540.	1.4	0
420	Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. <i>Cancer</i> , 1998, 83, 1142-52.	4.1	68
421	Assessment of Hormone Dependence of Comedo Ductal Carcinoma In Situ of the Breast. <i>Journal of the National Cancer Institute</i> , 1997, 89, 1059-1065.	6.3	44
422	Oestrogens, Beatson and endocrine therapy. <i>Endocrine-Related Cancer</i> , 1997, 4, 371-380.	3.1	15
423	Serum 1,25-Dihydroxyvitamin D May Be Related Inversely to Disease Activity in Breast Cancer Patients with Bone Metastases ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 118-122.	3.6	77
424	ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1997, 61, 145-149.	2.5	18
425	Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. <i>European Journal of Cancer</i> , 1997, 33, 2183-2193.	2.8	54
426	Review of recent trials of chemotherapy for advanced breast cancer: Studies excluding taxanes. <i>European Journal of Cancer</i> , 1997, 33, 2171-2182.	2.8	11
427	Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone. <i>British Journal of Cancer</i> , 1997, 75, 251-257.	6.4	89
428	Duration of remission to ICI 182,780 compared to megestrol acetate in tamoxifen resistant breast cancer. <i>Breast</i> , 1997, 6, 186-189.	2.2	27
429	Changes in the normal human breast throughout the menstrual cycle: relevance to breast carcinogenesis. <i>Endocrine-Related Cancer</i> , 1997, 4, 23-33.	3.1	18
430	Estrogen sensitivity of normal human breast tissue in vivo and implanted into athymic nude mice: Analysis of the relationship between estrogen-induced proliferation and progesterone receptor expression. <i>Breast Cancer Research and Treatment</i> , 1997, 45, 121-133.	2.5	235
431	Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. , 1997, 72, 608-613.		104
432	Investigation of mammary epithelial cell-bone marrow stroma interactions using primary human cell culture as a model of metastasis. , 1997, 73, 690-696.		20

#	ARTICLE	IF	CITATIONS
433	Recent advances in endocrine therapy of breast cancer. <i>BMJ: British Medical Journal</i> , 1997, 315, 863-866.	2.3	44
434	Dissociation between steroid receptor expression and cell proliferation in the human breast. <i>Cancer Research</i> , 1997, 57, 4987-91.	0.9	480
435	A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *. <i>European Journal of Cancer</i> , 1996, 32, 404-412.	2.8	248
436	New endocrine therapies for breast cancer. <i>European Journal of Cancer</i> , 1996, 32, 576-588.	2.8	79
437	Cancer genetics clinics. <i>European Journal of Cancer</i> , 1996, 32, 391-392.	2.8	22
438	Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.. <i>Journal of Clinical Oncology</i> , 1996, 14, 2000-2011.	1.6	371
439	Mobilisation kinetics of primitive haemopoietic cells following G-CSF with or without chemotherapy for advanced breast cancer. <i>Annals of Oncology</i> , 1996, 7, 1051-1057.	1.2	11
440	Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. <i>British Journal of Cancer</i> , 1996, 74, 300-308.	6.4	182
441	Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. <i>Breast Cancer Research and Treatment</i> , 1996, 41, 31-41.	2.5	42
442	New endocrine treatments for breast cancer: biological and clinical aspects. <i>Breast</i> , 1996, 5, 170-174.	2.2	5
443	Models of new antioestrogen action in vivo: primary tumours. <i>Breast</i> , 1996, 5, 186-191.	2.2	7
444	Clinical studies with the specific "pure"™ antioestrogen ICI 182780. <i>Breast</i> , 1996, 5, 192-195.	2.2	1
445	TUMOUR ANGIOGENESIS AS A PROGNOSTIC MARKER IN INFILTRATING LOBULAR CARCINOMA OF THE BREAST. , 1996, 180, 44-49.		46
446	Carcinomatous meningitis in solid tumours. <i>Annals of Oncology</i> , 1996, 7, 773-786.	1.2	93
447	Clues to the mechanisms of endocrine resistance from clinical studies in advanced breast cancer. <i>Endocrine-Related Cancer</i> , 1995, 2, 131-139.	3.1	7
448	Allelic imbalance on chromosome I in human breast cancer. II. Microsatellite repeat analysis. <i>Genes Chromosomes and Cancer</i> , 1995, 12, 24-31.	2.8	51
449	Entry into the tamoxifen prevention trial depends on women's estimates of the population risk of breast cancer. <i>Breast</i> , 1995, 4, 203-204.	2.2	2
450	"Should I Take HRT, Doctor?"™ Hormone Replacement Therapy in Women at Increased Risk of Breast Cancer and in Survivors of the Disease. <i>The Journal of the British Menopause Society</i> , 1995, 1, 9-17.	1.3	3

#	ARTICLE	IF	CITATIONS
451	The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone.. Endocrinology, 1995, 136, 164-171.	2.8	162
452	Oestrogen sulphotransferases in malignant and normal human breast tissue. Endocrine-Related Cancer, 1995, 2, 227-233.	3.1	24
453	A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. European Journal of Cancer, 1995, 31, 137-142.	2.8	97
454	Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet, The, 1995, 345, 989-990.	13.7	28
455	Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet, The, 1995, 345, 29-30.	13.7	301
456	The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology, 1995, 136, 164-171.	2.8	60
457	Dose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancer. Annals of Oncology, 1994, 5, 217-224.	1.2	13
458	Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant. Cancer, 1994, 74, 3135-3141.	4.1	113
459	Phenotypic heterogeneity in breast fibroblasts: Functional anomaly in fibroblasts from histologically normal tissue adjacent to carcinoma. International Journal of Cancer, 1994, 59, 25-32.	5.1	46
460	Tamoxifen withdrawal responses " chance observations or clinical clues to antioestrogen resistance?. Breast, 1994, 3, 199-201.	2.2	7
461	Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein. British Journal of Cancer, 1994, 70, 169-172.	6.4	53
462	Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. British Journal of Cancer, 1994, 70, 204-211.	6.4	73
463	The impact of genetic counselling on risk perception in women with a family history of breast cancer. British Journal of Cancer, 1994, 70, 934-938.	6.4	168
464	Cancer experience in the relatives of an unselected series of breast cancer patients. British Journal of Cancer, 1994, 70, 102-111.	6.4	34
465	Fetal-like fibroblasts: Their production of migration-stimulating factor and role in tumor progression. Cancer Treatment and Research, 1994, 71, 277-298.	0.5	13
466	Cyclical Activity and "Ageing"™ of the Human Breast: Clues to Assessment of Risk and Strategies for Prevention. , 1994, , 27-46.		4
467	Fortnightly Review: Familial breast cancer. BMJ: British Medical Journal, 1994, 308, 183-187.	2.3	71
468	Rapid haematological recovery after high-dose consolidation chemotherapy with peripheral blood progenitor cells (PBPC) as sole source of support collected at a single apheresis. Bone Marrow Transplantation, 1994, 13, 839-40.	2.4	5

#	ARTICLE	IF	CITATIONS
469	Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. <i>Cancer Research</i> , 1994, 54, 408-14.	0.9	215
470	Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. <i>British Journal of Cancer</i> , 1993, 67, 606-611.	6.4	100
471	High dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer. <i>British Journal of Cancer</i> , 1993, 67, 825-829.	6.4	37
472	Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. <i>European Journal of Cancer</i> , 1993, 29, 1141-1145.	2.8	154
473	Haemopoietic cells mobilised into the circulation by lenograstim as alternative to bone marrow for allogeneic transplants. <i>Lancet, The</i> , 1993, 341, 369.	13.7	84
474	Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide. <i>European Journal of Cancer</i> , 1993, 29, 209-217.	2.8	29
475	Perception of risk in women with a family history of breast cancer. <i>British Journal of Cancer</i> , 1993, 67, 612-614.	6.4	162
476	A linkage study in seven breast cancer families. <i>American Journal of Human Genetics</i> , 1993, 52, 786-8.	6.2	5
477	Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia. <i>Postgraduate Medical Journal</i> , 1992, 68, 434-439.	1.8	24
478	Original article: Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. <i>Annals of Oncology</i> , 1992, 3, 611-617.	1.2	151
479	Doxorubicin in advanced breast cancer: Influence of schedule on response, survival and quality of life. <i>European Journal of Cancer</i> , 1992, 28, 1023-1028.	2.8	62
480	Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast. <i>Journal of Pathology</i> , 1992, 167, 25-32.	4.5	120
481	Normal human breast xenografts activate N-nitrosodimethylamine: identification of potential target cells for an environmental nitrosamine. <i>British Journal of Cancer</i> , 1992, 66, 79-83.	6.4	7
482	Changes in the extracellular matrix of the normal human breast during the menstrual cycle. <i>Cell and Tissue Research</i> , 1992, 268, 167-177.	2.9	83
483	Prognostic relevance of serum hyaluronan levels in patients with breast cancer. <i>International Journal of Cancer</i> , 1992, 52, 873-876.	5.1	21
484	The Contribution of Perturbed Epithelial-Mesenchymal Interactions to Cancer Pathogenesis. , 1992, , 61-72.		0
485	Psychiatric morbidity in patients with advanced cancer of the breast: prevalence measured by two self-rating questionnaires. <i>British Journal of Cancer</i> , 1991, 64, 349-352.	6.4	176
486	Parathyroid hormone-related protein(50â€“69) and response to pamidronate therapy for tumour-induced hypercalcaemia. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 1629-1633.	0.7	42

#	ARTICLE	IF	CITATIONS
487	Migration stimulating activity in serum of breast cancer patients. <i>Lancet</i> , The, 1991, 337, 130-133.	13.7	27
488	Treating bony metastases.. <i>BMJ: British Medical Journal</i> , 1991, 303, 429-430.	2.3	9
489	Screening for psychiatric morbidity in patients with advanced breast cancer: validation of two self-report questionnaires. <i>British Journal of Cancer</i> , 1991, 64, 353-356.	6.4	244
490	Objective measurement of therapeutic response in breast cancer using tumour markers. <i>British Journal of Cancer</i> , 1991, 64, 757-763.	6.4	57
491	Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. <i>International Journal of Cancer</i> , 1991, 48, 206-210.	5.1	117
492	Prospective assessment of the role of five tumour markers in breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 1991, 33, 403-410.	4.2	34
493	The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. <i>Calcified Tissue International</i> , 1991, 49, 433-435.	3.1	50
494	The Systemic Treatment of Bone Metastases. , 1991, , 121-147.		7
495	Heterogeneity amongst fibroblasts in the production of migration stimulating factor (MSF): Implications for cancer pathogenesis. <i>Exs</i> , 1991, 59, 127-146.	1.4	15
496	Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate. <i>British Journal of Cancer</i> , 1990, 61, 123-125.	6.4	28
497	C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis. <i>British Journal of Cancer</i> , 1990, 61, 39-45.	6.4	72
498	Tenascin distribution in the normal human breast is altered during the menstrual cycle and in carcinoma. <i>Differentiation</i> , 1990, 42, 199-207.	1.9	62
499	Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 25, 435-439.	2.3	20
500	4 New endocrine approaches to breast cancer. <i>Bailliere's Clinical Endocrinology and Metabolism</i> , 1990, 4, 67-84.	1.0	6
501	Assessment of four monoclonal antibodies as serum markers in breast cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1990, 26, 1127-1132.	0.7	24
502	Tamoxifen as an Agonist for Metastatic Breast Cancer. , 1990, , 49-58.		11
503	Growth Factor Assisted Chemotherapy The Manchester Experience. <i>Novartis Foundation Symposium</i> , 1990, 148, 201-220.	1.1	2
504	Clinical evidence for the involvement of oestrogen in the development and progression of breast cancer. <i>Proceedings of the Royal Society of Edinburgh Section B Biological Sciences</i> , 1989, 95, 49-57.	0.2	8

#	ARTICLE	IF	CITATIONS
505	Epidermal and transforming growth factor $\hat{\pm}$ in patients with breast tumours. British Journal of Cancer, 1989, 59, 605-609.	6.4	60
506	The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. British Journal of Cancer, 1989, 60, 121-125.	6.4	275
507	West Midlands Oncology Association trials of adjuvant chemotherapy in operable breast cancer: results after a median follow-up of 7 years. I. Patients with involved axillary lymph nodes. British Journal of Cancer, 1989, 60, 911-918.	6.4	29
508	The expression of milk fat globule antigens within human mammary tumours: Relationship to steroid hormone receptors and response to endocrine treatment. European Journal of Cancer & Clinical Oncology, 1989, 25, 459-467.	0.7	12
509	Serum bioactive lactogenic hormone levels in women with familial breast cancer and their relatives. European Journal of Cancer & Clinical Oncology, 1989, 25, 1719-1725.	0.7	10
510	The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 9499-9503.	7.1	316
511	Expression of differentiation antigens within human mammary tumours is related to response to endocrine therapy and survival. International Journal of Cancer, 1988, 42, 154-158.	5.1	8
512	The effect of age and menstrual cycle upon proliferative activity of the normal human breast. British Journal of Cancer, 1988, 58, 163-170.	6.4	301
513	Bisphosphonates and bone metastases. British Journal of Cancer, 1988, 58, 556-557.	6.4	18
514	The relationship of body weight to response to endocrine therapy, steroid hormone receptors and survival of patients with advanced cancer of the breast. British Journal of Cancer, 1988, 58, 631-634.	6.4	25
515	In situ hybridisation and S1 mapping show that the presence of infiltrating plasma cells is associated with poor prognosis in breast cancer. British Journal of Cancer, 1988, 58, 715-722.	6.4	13
516	Cellular aspects of breast cancer: Workshop report. European Journal of Cancer & Clinical Oncology, 1988, 24, 21-28.	0.7	2
517	The definition of the "no change" category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. European Journal of Cancer & Clinical Oncology, 1988, 24, 1567-1572.	0.7	95
518	Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma.. BMJ: British Medical Journal, 1988, 297, 772-773.	2.3	88
519	Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy. BMJ: British Medical Journal, 1988, 296, 811-814.	2.3	57
520	The Possible Role of Abnormal Fibroblasts in the Pathogenesis of Breast Cancer. , 1988, , 142-157.		4
521	Hypothesis: Persistent Expression of Fetal Phenotypic Characteristics by Fibroblasts Is Associated with an Increased Susceptibility to Neoplastic Disease. Pathobiology, 1987, 55, 11-17.	3.8	22
522	DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast. British Journal of Cancer, 1987, 55, 553-559.	6.4	70

#	ARTICLE	IF	CITATIONS
523	Infiltrating lobular carcinoma of the breast: Response to endocrine therapy and survival. European Journal of Cancer & Clinical Oncology, 1987, 23, 979-982.	0.7	33
524	FIBROBLASTS FROM RELATIVES OF PATIENTS WITH HEREDITARY BREAST CANCER SHOW FETAL-LIKE BEHAVIOUR IN VITRO. Lancet, The, 1987, 329, 1455-1457.	13.7	56
525	Cis-platinum and ovarian carcinoma. In vitro chemosensitivity of cultured tumour cells from patients receiving high dose cis-platinum as first line treatment. British Journal of Cancer, 1987, 56, 763-773.	6.4	20
526	Endocrine therapy for advanced carcinoma of the breast: effect of tumor heterogeneity and site of biopsy on the predictive value of progesterone receptor estimations. Cancer Research, 1987, 47, 296-9.	0.9	12
527	Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. Cancer Research, 1987, 47, 300-4.	0.9	53
528	TUMOUR INFORMATION FROM NEEDLE BIOPSY. Lancet, The, 1986, 328, 1342-1343.	13.7	0
529	MECHANISM OF ACTION OF ADJUVANT CHEMOTHERAPY IN EARLY BREAST CANCER. Lancet, The, 1986, 328, 411-414.	13.7	85
530	A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer.. Journal of Clinical Oncology, 1986, 4, 1326-1330.	1.6	154
531	Occurrence of a fetal fibroblast phenotype in familial breast cancer. International Journal of Cancer, 1986, 37, 831-836.	5.1	63
532	Molecular expression of epitopes recognized by monoclonal antibodies HMFG-1 and HMFG-2 in human breast cancers: Diversity, variability and relationship to prognostic factors. International Journal of Cancer, 1986, 38, 89-96.	5.1	21
533	A New Hormonal Therapy for Prostatic Cancer: Long-term Clinical and Hormonal Response. British Journal of Urology, 1986, 58, 534-538.	0.1	15
534	Testosterone and Gonadotrophin Profiles in Patients on Daily or Monthly LHRH Analogue ICI 118630 (Zoladex) Compared with Orchiectomy. British Journal of Urology, 1986, 58, 539-544.	0.1	20
535	Systemic Treatment and Survival in Carcinoma of the Breast. , 1986, , 303-312.		0
536	Infiltrating lobular carcinoma of the breast.. BMJ: British Medical Journal, 1985, 291, 1371-1372.	2.3	22
537	Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.. BMJ: British Medical Journal, 1985, 290, 185-187.	2.3	56
538	Carcinomatous meningitis associated with infiltrating lobular carcinoma of the breast. European Journal of Surgical Oncology, 1985, 11, 33-6.	1.0	37
539	Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.. BMJ: British Medical Journal, 1984, 289, 831-831.	2.3	0
540	A comparison of three assays used for the in vitro chemosensitivity testing of human tumours. British Journal of Cancer, 1984, 49, 57-63.	6.4	29

#	ARTICLE	IF	CITATIONS
541	The prognostic significance of two epithelial membrane antigens expressed by human mammary carcinomas. <i>International Journal of Cancer</i> , 1984, 33, 299-304.	5.1	102
542	Dibromodulcitol, mitomycin C and vinblastine (DMV) chemotherapy in advanced breast cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1984, 20, 873-876.	0.7	9
543	STEROID-HORMONE RECEPTORS AND SURVIVAL AFTER FIRST RELAPSE IN BREAST CANCER. <i>Lancet, The</i> , 1984, 323, 588-591.	13.7	160
544	CONTROLLED TRIAL OF ADJUVANT CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL FOR BREAST CANCER. <i>Lancet, The</i> , 1984, 324, 307-311.	13.7	65
545	A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. <i>British Journal of Cancer</i> , 1984, 50, 23-30.	6.4	331
546	Twenty-four hour combination chemotherapy: a feasibility study with implications for improved adjuvant treatment of breast cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1983, 19, 1-4.	0.7	11
547	TREATMENT OF ADVANCED PROSTATIC CANCER WITH LHRH ANALOGUE ICI 118630: CLINICAL RESPONSE AND HORMONAL MECHANISMS. <i>Lancet, The</i> , 1983, 322, 415-419.	13.7	63
548	CONTROLLED TRIAL OF ADJUVANT CHEMOTHERAPY WITH MELPHALAN FOR BREAST CANCER. <i>Lancet, The</i> , 1983, 321, 839-843.	13.7	70
549	Variation of receptor status in cancer of the breast. <i>British Journal of Cancer</i> , 1983, 47, 511-515.	6.4	23
550	Intermediate dose single agent cyclophosphamide chemotherapy of advanced breast cancer. <i>Clinical Oncology</i> , 1983, 9, 251-6.	0.1	1
551	The clinical value of immunohistochemically demonstrable CEA in breast cancer: a possible method of selecting patients for adjuvant chemotherapy. <i>British Journal of Cancer</i> , 1982, 46, 757-764.	6.4	26
552	Localisation of Malignant Germ-Cell Tumours by External Scanning After Injection of Radiolabelled Anti-Alpha-Fetoprotein. <i>Journal of Urology</i> , 1982, 127, 835-836.	0.4	0
553	Assessment of renal function during high-dose cis-platinum therapy in patients with ovarian carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1982, 8, 281-4.	2.3	27
554	VAP-cyclo: a short intensive regimen of chemotherapy for advanced breast cancer. <i>Cancer Treatment Reports</i> , 1982, 66, 1999-2000.	0.5	1
555	Serum proteins as tumour markers for breast cancer. <i>British Journal of Cancer</i> , 1981, 43, 542-545.	6.4	8
556	Effect of Altitude on Water Excretion. <i>Clinical Science</i> , 1980, 59, 11P-11P.	4.3	0
557	Effect of sodium butyrate on synthesis of specific proteins by human breast-carcinoma cells. <i>British Journal of Cancer</i> , 1980, 42, 616-619.	6.4	5
558	HISTOLOGICAL DETECTION OF ÅSTROGEN RECEPTOR IN HUMAN BREAST CARCINOMAS. <i>Lancet, The</i> , 1980, 315, 171-173.	13.7	66

#	ARTICLE	IF	CITATIONS
559	Tumour markers in breast cancer. British Journal of Cancer, 1979, 40, 710-718.	6.4	34
560	The synthesis of the glycoprotein hormone α subunit by human breast carcinomas. European Journal of Cancer, 1979, 15, 693-702.	0.9	13
561	The Use of Milk-Protein Estimation to Assess the Effect of Hormones on Human Breast in Organ Culture. Clinical Science, 1979, 56, 22P-22P.	4.3	0
562	An Automated Test for Antigen- α Antibody Complexes in Human Sera with a Low-Affinity Igm Antiserum. Clinical Science, 1979, 56, 30P-31P.	4.3	0
563	PREDICTIVE CLASSIFICATION OF HUMAN BREAST CARCINOMAS BASED ON LACTALBUMIN SYNTHESIS. Lancet, The, 1977, 310, 14-16.	13.7	29
564	Release of Colony-Stimulating Activity from the Isolated Perfused Rat Liver. Clinical Science and Molecular Medicine, 1976, 50, 539-544.	0.8	1
565	The Effects of Drugs that Cause Neutropenia upon Colony Formation by Bone Marrow Cells in Semi-Solid Agar. Clinical Science and Molecular Medicine, 1974, 46, 619-628.	0.8	11
566	Labor Market Segmentation in Urumqi, Xinjiang: Exposing Labor Market Segments and Testing the Relationship between Migration and Segmentation. SSRN Electronic Journal, 0, , .	0.4	2
567	Technological relatedness and asymmetrical firm productivity gains under market reforms in China. Cambridge Journal of Regions, Economy and Society, 0, , rsw024.	3.0	11
568	Clustering Effects on Firm Exporting with Productivity-Enhancing R&D in China. SSRN Electronic Journal, 0, , .	0.4	1
569	Innovation and Firm Performance in the People's Republic of China: A Structural Approach with Spillovers. SSRN Electronic Journal, 0, , .	0.4	6
570	Urban Agglomeration, Selection and the Impact of Policy Distortions on Firm Productivity in China. SSRN Electronic Journal, 0, , .	0.4	3
571	A Structural Model of Indigenous Innovation and Catch-Up for Developing Economies. SSRN Electronic Journal, 0, , .	0.4	1
572	Minimum Wage Impacts on Inequality, Job Formality and the Ethnic Wage Gap in Urban China. SSRN Electronic Journal, 0, , .	0.4	2
573	Ethnicity, Start-Up Finance, and Entrepreneurship in China. SSRN Electronic Journal, 0, , .	0.4	1
574	Direct and Spillover Effects of Targeted Cash Transfers on Ethnic Rural-Urban Migration in China. SSRN Electronic Journal, 0, , .	0.4	1
575	Inter-Industry Relatedness, Absorptive Capacity and Firm Productivity in a Transitioning Chinese Economy. SSRN Electronic Journal, 0, , .	0.4	3
576	Picking Winners in China: Do Subsidies Matter for Indigenous Innovation and Firm Productivity?. SSRN Electronic Journal, 0, , .	0.4	1

#	ARTICLE	IF	CITATIONS
577	Minimum Wages, Spillovers and the Unconditional Wage Distribution in Urban China: Do Ethnic Minorities Benefit?. SSRN Electronic Journal, 0, , .	0.4	0
578	Heterogenous Impacts of China's Economic and Development Zone Program. SSRN Electronic Journal, 0, , .	0.4	0